Introduction: Urinary tract infections (UTIs) are common in patients with chronic kidney disease. A treatment option in recurrent UTI is sublingual bacterial vaccination. The objective of this study was to determine the response to vaccination in nephrologic patients with recurrent UTI.
Method: Quasi-experimental study before-after (15 months) in patients with recurrent UTI from the outpatient nephrology consultation. After receiving antibiotic treatment for each UTI, patients took one cycle of the sublingual bacterial vaccine Uromune? for three months. Sociodemographic data, associated risk factors, analysis, UTI in the previous and subsequent six months, microorganisms, concomitant antibiotic treatment, response to treatment and resolution of UTI were collected.
Results: Twenty-six patients (80.8% female) of 61.9 ? 18.4 years, 46.2% with diabetes and 47.7% with impaired renal function were included. The episodes of UTI were 3.62 ? 1.77 (1-7) before and 1.69 ? 1.62 (0-5) after vaccination. In total, 184 urine cultures were collected: 74.9% positive, 16.9% negative and 8.2% contaminated. The most frequent bacteria were Escherichia coli (55.4%), Enterococcus faecalis (6%) and Enterobacter cloacae (2.7%). Fifty percent had voiding syndrome, which was inversely associated with age (p < 0.05); 26.9% did not have a UTI again and 73.1% had fewer episodes. Patients with advanced chronic disease (stages 4-5) reponded worse to the vaccine (92.9% vs 50%, p =0.025).
Conclusions: Sublingual bacterial vaccination is a good treatment option in recurrent UTI of nephrologic patients, being more effective in those with better renal function.
Vaqué J, Rodrigo JA. Prevalencia de las infecciones en los hospitales españoles. Estudio EPINE. Resultados de los estudios de 2004, 2005, 2006 y 2007 y evolución 1990-2007: 18 años. Resultados generales. Medicina Preventiva. 2008;14(1):1-75.
XAu H, Gasparini A, Ishigami J, Mzayen K, Su G, Barany P, et al. eGFR and the Risk of Community-Acquired Infections. Clin J Am Soc Nephrol. 2017. https://dx.doi.org/10.2215/CJN.00250117.
Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end- stage renal disease compared with the general population. Kidney Int. 2000;58(4):1758-64. https://dx.doi.org/10.1111/j.1523-1755.2000.00337.x.
Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis. 2006;13(3):199-204. https://dx.doi.org/10.1053/j.ackd.2006.04.004.
Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis. 2012;59(3):356-63. https://dx.doi.org/10.1053/j.ajkd.2011.07.012.
James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 2009;54(1):24-32. https://dx.doi.org/10.1053/j.ajkd.2009.04.005.
Mc Donald HI, Thomas SL, Nitsch D. Chronic kidney disease as a risk factor for acute community-acquired infections in high-income countries: a systematic review. BMJ Open. 2014;4(4):e0044100. http://dx.doi.org/10.1136/bmjopen-2013-004100.
Cheikh-Hassan HI, Tang M, Djurdjev O, Langsford D, Sood MM, Levin A. Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality. Kidney Int. 2016;90(4):897-904. https://dx.doi.org/10.1016/j.kint.2016.07.013.
García Agudo R, Panizo N, Proy-Vega B, García-Martos P, Fernández-Rodríguez A. Infección del tracto urinario en la enfermedad renal crónica. Rev. Colomb. Nefrol. 2020;7(1):70-83. https://doi.org/10.22265/acnef.7.1.264.
Benito-Villalvilla C, Cirauqui C, Díez-Rivero CM, Casanovas M, Subiza JL, Palomares O. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Mucosal Immunol. 2016;10(4):924-935. https://dx.doi.org/10.1038/mi.2016.112.
Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active. E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002;19(6):451-6. https://dx.doi.org/10.1016/s0924-8579(02)00106-1.
Bauer HW, Alloussi S, Egger G, Blümlein HM, Cozma G, Schulman CC. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol. 2005;47(4):542-8. https://dx.doi.org/10.1016/j.eururo.2004.12.009.
Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents 2009;33(2):111-9. https://dx.doi.org/10.1016/j.ijantimicag.2008.08.011.
Lorenzo-Gómez MF, Padilla-Fernández B, García-Criado FJ, Mirón-Canelo JA, Gil-Vicente A, Nieto-Huertos A, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versusprophylactic treatment with antibiotics. Int Urogynecol J. 2013;24(1):127-34. https://dx.doi.org/10.1007/s00192-012-1853-5.
Lorenzo-Gómez MF, Padilla-Fernández B, García-Cenador MB, Virseda- Rodríguez AJ, Martín-García I, Sánchez-Escudero A, et al. Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent uninary tract infections. Front Cell Infect Microbiol. 2015;5:50. https://dx.doi.org/10.3389/fcimb.2015.00050.
Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10(10):CD001321. https://dx.doi.org/10.1002/14651858.CD001321.pub5.
Stapleton AE, Dziura J, Hooton TM, Cox MB, Yarova-Yarovaya Y, Chen S, et al. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clinic Proc. 2012;87(2):143-50. https://dx.doi.org/10.1016/j.mayocp.2011.10.006.
Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med. 2011;171(14):1270-8. https://dx.doi.org/10.1001/archinternmed.2011.306.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2020 Revista Colombiana de Nefrología